Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial

Alimentary Pharmacology & Therapeutics
W TremaineP P Metzger

Abstract

Bismuth carbomer liquid enemas are equivalent to mesalamine enemas for active distal ulcerative colitis. In this study, the efficacy and safety of bismuth carbomer foam enemas for active chronic pouchitis was determined in a placebo-controlled trial. Forty adult patients with active chronic pouchitis were randomly assigned into either concurrent therapy for pouchitis or no concurrent therapy. Topical corticosteroids and mesalamine were withdrawn prior to the study. Patients received either bismuth carbomer (270 mg elemental bismuth) (n = 20) or placebo (n = 20) foam enemas for 3 weeks. Clinical assessment was performed at baseline and at 3 weeks using the pouchitis disease activity index score which incorporates symptoms, endoscopy and histology. Serum bismuth concentrations were determined by atomic absorption spectrophotometry. At 3 weeks nine of 20 patients (45%) in both the bismuth and placebo groups had improved. Ten patients discontinued prematurely because of worse diarrhoea (three in each group) or abdominal cramping after enema use (one from the bismuth group and three from the placebo group). No other side-effects were noted. Serum bismuth concentrations were negligible in all patients. Bismuth carbomer foam enemas (2...Continue Reading

Citations

Feb 7, 2007·Diseases of the Colon and Rectum·Bo ShenBret A Lashner
Sep 20, 2005·Current Gastroenterology Reports·Bo Shen, Bret A Lashner
Oct 5, 2010·Current Gastroenterology Reports·Udayakumar Navaneethan, Bo Shen
Sep 5, 2002·Current Treatment Options in Gastroenterology·Jean Perrault
Jan 21, 2006·Current Treatment Options in Gastroenterology·Bo Shen, Bret Lashner
Oct 21, 2004·Best Practice & Research. Clinical Gastroenterology·Paolo GionchettiFilippo Pierangeli
Jun 8, 2001·Gastroenterology Clinics of North America·L Stocchi, J H Pemberton
Jun 6, 2002·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Jun 26, 1999·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Feb 22, 2002·Alimentary Pharmacology & Therapeutics·A SambuelliJ C Bai
Oct 13, 2006·Current Opinion in Gastroenterology·M Cruz-CorreaT M Bayless
Mar 22, 2002·Journal of Clinical Gastroenterology·Seymour Katz
Feb 24, 1999·Inflammatory Bowel Diseases·W J SandbornD P Jewell
Nov 27, 2001·Inflammatory Bowel Diseases·B ShenV W Fazio
Jul 13, 2002·Journal of Wound, Ostomy, and Continence Nursing : Official Publication of the Wound, Ostomy and Continence Nurses Society·Mikel Gray, Janice C Colwell
Jul 8, 2005·Journal of Clinical Gastroenterology·Seymour Katz
Apr 28, 2004·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·D A L MacafeeC Maxwell-Armstrong
Sep 12, 2008·World Journal of Gastroenterology : WJG·Livia BianconeFrancesco Pallone
Jul 24, 2008·Journal of Gastroenterology·Yasumi ArakiToshihiro Noake
Apr 14, 2006·Alimentary Pharmacology & Therapeutics·D S Pardi, W J Sandborn
Jan 6, 2006·The American Journal of Gastroenterology·Bo ShenBret A Lashner
Dec 25, 2010·Therapeutic Advances in Gastroenterology·S D McLaughlinP J Ciclitira
Dec 22, 2017·Alimentary Pharmacology & Therapeutics·F BärUNKNOWN German IBD Study Group
Nov 26, 2015·The Cochrane Database of Systematic Reviews·Siddharth SinghDarrell S Pardi
Oct 13, 2009·Expert Review of Gastroenterology & Hepatology·Udayakumar Navaneethan, Bo Shen
May 29, 2019·The Cochrane Database of Systematic Reviews·Nghia NguyenSiddharth Singh
Jun 18, 2015·Journal of Clinical Gastroenterology·Hans H HerfarthKim L Isaacs
Dec 1, 2019·The Cochrane Database of Systematic Reviews·Nghia NguyenSiddharth Singh
Jul 1, 2013·Frontline Gastroenterology·A Hillary Steinhart, Ofer Ben-Bassat
Feb 18, 2020·Frontiers in Medicine·Zaid S Ardalan, Miles P Sparrow
Apr 25, 2018·Inflammatory Bowel Diseases·Robin L DalalDavid A Schwartz
Jul 1, 2020·Gastroenterología y hepatología·Manuel Barreiro-de AcostaUNKNOWN en representación de GETECCU
Jun 29, 2021·Inflammatory Bowel Diseases·Rocio SedanoVipul Jairath
Jun 24, 2021·Journal of Crohn's & Colitis·Tim RaineGarret Cullen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.